UNSPSC 51282202: Cefoxitin

This classification denotes a cephalosporin antibiotic with the molecular formula C16H17N3O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6OEV9DX57Y, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, (6r-cis)- but generally known as cefoxitin, which bears US NIH Compound Identifier 37194. European Medicines Agency schedules Cefoxitin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07409MIG.

UNSPSC 51282202 Cefoxitin is a Commodity code that in practice covers pharmaceutical products and medical supplies procured by state and local health agencies, though recent solicitations tagged to this code show minimal actual cefoxitin purchasing and instead reflect broader pharmaceutical and medical-supply procurement patterns. State and local governments use this code to source generic pharmaceuticals, over-the-counter products, emergency medical supplies, naloxone, and related health-system consumables through competitive bid and cooperative purchasing mechanisms. Issuing bodies include state health and human services departments, county health agencies, municipal fire departments, and multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and Texas Health and Human Services Commission represent state-level aggregated demand, while Seminole County, Florida and the City of Tampa represent county and municipal health procurement, with the latter sheltering purchases to certified Small Local Business Enterprises under a 5 percent bid discount.

Recent activity concentrates in Florida and Texas, with broader geographic participation through cooperative purchasing vehicles spanning multiple states including Minnesota and Oregon. Representative recent opportunities include the Minnesota MMCAP generic multi-source pharmaceuticals and OTC products RFP (due March 26, 2026), which establishes statewide contracts through three authorized wholesalers with 75 percent evaluation weight on price competitiveness and mandatory cGMP and DSCSA compliance; the Texas HHS Commission Request for Information on direct-to-manufacturer prescription programs (response deadline April 3, 2026), seeking vendor capabilities for self-insured employer and state-agency contracting outside traditional PBM and GPO channels; Seminole County's IFB for naloxone and drug deactivation systems (1,900 units and 800 units annually, due July 26, 2023); and the City of Tampa's sheltered IFB for medical and first aid supplies to the Fire Department Rescue Division (169 line items, estimated contract value $700,000, due March 13, 2026, with SLBE preference and 5 percent discount available up to $10,000). Cooperative purchasing and state aggregated procurements dominate the current activity level, with pricing competitiveness and supply-chain compliance as primary evaluation drivers.